Smith & Nephew plc (SNN) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlighted strong financial performance with a 21% EPS increase and a $500 million share buyback. Trading margins expanded, and ROIC improved. Product updates like the CORI Shoulder platform and REGENETEN's market potential were promising. Despite some uncertainties in China and the skin substitutes market, the company maintains a positive outlook for 2026 with growth in key areas. The Q&A reflected confidence in strategic initiatives and competitive positioning, supporting a positive sentiment.
Key Financial Performance
Underlying revenue growth 5.3% for the full year, with all three business units growing by over 5%. Growth was driven by innovations and products launched in the last 5 years, contributing over 60% of the growth.
Margin expansion 160 basis points, driven by enterprise-wide cost savings, manufacturing network optimization, productivity improvements, and portfolio rationalization.
Free cash flow $840 million, a 52.5% increase year-on-year, attributed to higher profitability, reduced restructuring charges, and improved working capital management.
Q4 revenue $1.7 billion, representing 6.2% underlying growth and 8.3% reported growth, with a 210 bps tailwind from foreign exchange.
Orthopaedics growth 7.9% underlying growth in Q4, the strongest quarterly growth in over 2 years, driven by product launches like CATALYSTEM and LEGION MS, and increased CORI placements.
Sports Medicine & ENT growth 7.3% growth in Q4, driven by double-digit growth in Joint Repair and products like REGENETEN and Q-FIX KNOTLESS.
Advanced Wound Management growth 2.8% growth in Q4, with Advanced Wound Care growing 4.4%. Growth was supported by new product launches like ALLEVYN COMPLETE CARE.
Trading profit $1.2 billion for the full year, a $162 million increase, resulting in a 160 bps trading margin expansion to 19.7%. This was driven by revenue leverage, cost savings, and operational efficiencies.
Adjusted earnings per share Grew by 21% to $1.02, driven by the $500 million share buyback and higher profitability.
ROIC (Return on Invested Capital) Increased by 170 bps to 8.3%, or 330 bps excluding the 160 bps headwind from portfolio rationalization, driven by trading margin expansion and better asset utilization.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Innovation: Over 60% of growth in 2025 came from products launched in the last 5 years. Innovations like Q-FIX, REGENETEN, FASTSEAL, LEGION CONCELOC, CATALYSTEM, EVOS, AETOS, PICO, and LEAF delivered double-digit growth.
New Product Launches: Plans to launch LANDMARK knee system in 2026, which combines advanced kinematics, personalization, and robotic enablement. Also, ALLEVYN COMPLETE CARE was launched for wound care.
Acquisition: Acquired Integrity Orthopaedics for up to $450 million, including performance-based payments. This acquisition adds Tendon Seam, an innovative rotator cuff repair system.
Geographic Growth: Revenue growth was broad-based across regions: U.S. grew 5.6%, other established markets 7.2%, and emerging markets 6.4%. Excluding China, growth was 7.2%.
China Market Impact: China VBP headwinds peaked in 2025, reducing growth by 170 bps. However, the impact is expected to be smaller in 2026.
Margin Expansion: Achieved 160 bps margin expansion in 2025, driven by cost savings, manufacturing optimization, and productivity improvements.
Cash Flow: Free cash flow increased by 52.5% to $840 million in 2025, enabling a $500 million share buyback.
Operational Efficiencies: Implemented Ortho360 operating model, reducing inventory and improving capital efficiency.
RISE Strategy: Launched RISE strategy to accelerate growth and improve returns, focusing on innovation, scaling investments, and operational efficiency.
12-Point Plan: Completed the 12-Point Plan, achieving $280 million in cumulative savings by the end of 2025.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
China VBP (Volume-Based Procurement): Significant headwinds from VBP in China have impacted margins and revenue growth, particularly in Sports Medicine and ENT. Although the impact is expected to be smaller in 2026, it remains a challenge.
CMS reimbursement changes: Changes to CMS reimbursement policies for skin substitutes in the U.S. are expected to create a short-term value reset, particularly in the physician office and mobile settings, impacting the Advanced Wound Management segment.
Tariffs and cost inflation: The company faces $60 million in tariff-related costs in 2026, up from $17 million in 2025, along with ongoing raw material cost inflation.
U.S. Knees market performance: Inconsistent quarterly performance in the U.S. Knees market has been noted, with deliberate trade-offs between growth, profit, and asset efficiency expected to result in a softer first quarter in 2026.
Integration of acquisitions: The acquisition of Integrity Orthopaedics is expected to be dilutive to trading profit in 2026 and only accretive starting in 2028, posing short-term financial challenges.
Inventory management: While progress has been made in reducing inventory, further reductions are required, particularly in Orthopaedics, to meet industry benchmarks.
Economic and market uncertainties: Foreign exchange volatility and economic uncertainties in emerging markets, including localized weaknesses in distributor-led markets, pose risks to revenue growth.
Regulatory hurdles: Awaiting FDA approval for new products like TESSA introduces uncertainty and potential delays in product launches.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects 6% organic revenue growth in 2026, driven by continued growth in Orthopaedics, Sports Medicine, and Advanced Wound Management. Growth will be supported by new product launches and market expansion.
Trading Profit Growth: Trading profit is expected to grow by 8% on an organic basis in 2026, with a total trading profit of around $1.3 billion, including the impact of the Integrity Orthopaedics acquisition.
Orthopaedics Margin Expansion: The company anticipates further margin expansion in Orthopaedics through 2028, driven by revenue growth, manufacturing optimization, and the Ortho360 operating model.
Free Cash Flow: Free cash flow is projected to be around $800 million in 2026, with improvements driven by profit growth and operational efficiencies.
ROIC: Return on invested capital (ROIC) is expected to exceed 10% in 2026, excluding the Integrity Orthopaedics acquisition, with further improvements anticipated in subsequent years.
Product Launches: The company plans to launch 16 new products in 2026, including the LANDMARK knee system and ALLEVYN COMPLETE CARE dressing, which are expected to drive growth.
Market Trends: The company expects growth in the ASC (Ambulatory Surgery Center) channel, supported by tray-efficient implants and the CORI robotic platform. Additionally, the CMS reimbursement changes in the U.S. are expected to create a more sustainable market for skin substitutes.
Strategic Acquisitions: The acquisition of Integrity Orthopaedics is expected to be marginally dilutive to trading profit in 2026, neutral in 2027, and accretive starting in 2028. The acquisition aligns with the company's strategy to invest in high-growth clinical segments.
Midterm Financial Targets: The company aims for a 6%-7% organic revenue CAGR, 9%-10% trading profit CAGR, more than $1 billion in free cash flow by 2028, and 12%-13% ROIC.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Increase: The full year dividend is proposed to be $0.391 per share, an increase of 4.3% year-on-year.
Share Buyback Program: Completed a $500 million share buyback program in the second half of 2025.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the revenue growth expectations for 2026 and the phasing through the quarters?
A:The company expects 6% revenue growth in 2026, driven by multiple sources of growth across business units and innovation. Growth will be weighted towards the second half of the year, with Q1 being softer due to one fewer trading day and weaker U.S. Knees. The first half is expected to deliver 4.5%-5% growth, while the second half will deliver 7.5%-8% growth, resulting in an overall 6% growth for the year.
Q:What is the status and outlook for the CORI Shoulder platform?
A:The CORI Shoulder platform, launched in mid-2025, offers a complete and differentiated solution for shoulder surgeries, including reverse and anatomic procedures. It integrates preoperative planning, intraoperative, and postoperative insights, making it a comprehensive tool for surgeons.
Q:What is the outlook for Joint Repair in China and its impact on overall growth?
A:Joint Repair in China has annualized, and the company expects clean growth without the drag from China VBP. Excluding China, the company achieved high single-digit growth across geographies and categories. The impact of AET and ENT in China will be fully annualized by late 2026, with a relatively small impact on the group level.
Q:What are the plans for capital allocation and M&A?
A:The company prioritizes investments in organic growth through R&D and M&A. M&A will focus on scaling strengths in Sports and Wound. The acquisition of Integrity aligns with this strategy, enhancing the company's position in biomechanical repair and complementing its biologics portfolio.
Q:What is the company's perspective on the skin substitutes market and its assumptions for 2026?
A:The company expects a 15%-20% revenue reduction in skin substitutes due to a 20%-25% price reduction, offset by stable or slightly positive volumes. The market is adapting to CMS reimbursement changes, with uncertainty in physician office and mobile channels. Long-term, the company is optimistic about the segment due to clinical unmet needs and demographic trends.
Q:What is the significance of the portfolio rationalization and inventory write-down?
A:The $159 million inventory write-down is solely due to portfolio rationalization, representing a 2/3 reduction in Ortho SKUs and a 10% reduction in Sports SKUs, which account for only 7% of sales. This move simplifies the portfolio and focuses on offering the latest products.
Q:What is the contribution of REGENETEN to the Sports Medicine business and its market potential?
A:REGENETEN contributes multiple hundred million dollars to the Sports Medicine business and addresses a $1.2 billion market, including $875 million in biomechanical repair and the rest in biologics. The product has shown significant growth due to clinical evidence and commercial channel strength.
Q:What is the company's strategy for the LANDMARK Knee launch?
A:The LANDMARK Knee will launch in late 2026 with cementless options, followed by cemented options in early 2027. The platform combines personalization, ease of implantation, and trade efficiency, targeting ASC settings. The launch will be capital-efficient, with growth expected in Q3 and Q4 of 2026.
Q:What is the company's response to competition in the handheld robotic space and the J&J Ortho business spin-off?
A:The company emphasizes CORI as a versatile robotic platform for various settings, not just ASCs. It is confident in its competitive position due to CORI's features and benefits. Regarding J&J's spin-off, the company remains focused on its priorities and expects to maintain competitiveness.
Q:What is the company's outlook for the China market in 2026?
A:The company expects flat sales in Greater China in 2026 compared to 2025, with Sports recovering slightly due to successful channel inventory management. However, AET and ENT will see declines, resulting in a neutral top-line impact. The bottom-line impact will be a $15-$20 million reduction due to VBP.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the exact contribution of REGENETEN to the Sports Medicine business, only stating it contributes 'multiple hundred million.' Additionally, they did not provide precise quarterly guidance for skin substitutes, citing market uncertainty.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ALLEVYN COMPLETE
AWD
Budgeting saving
COMPLETE CARE
DSI day
Day inventory
Deepak
ENT digit
Hips Trauma
Integrity Orthopaedics
Joint Repair
LEAF
Landmark
Ortho model
Orthopaedics Medicine
RISE
ROIC
Trauma Extremities
acquisition Integrity
basis trading
bp
buyback
cash flow
day sale
efficiency
leverage
margin expansion
portfolio rationalization
reimbursement
restructuring charge
share
softness
trading basis
SNN Transcript
Smith & Nephew plc (SNN) Q4 2025 Earnings Call Transcript
Positive3-2
The earnings call highlighted strong financial performance with a 21% EPS increase and a $500 million share buyback. Trading margins expanded, and ROIC improved. Product updates like the CORI Shoulder platform and REGENETEN's market potential were promising. Despite some uncertainties in China and the skin substitutes market, the company maintains a positive outlook for 2026 with growth in key areas. The Q&A reflected confidence in strategic initiatives and competitive positioning, supporting a positive sentiment.
Smith & Nephew plc (SNN) Q2 2025 Earnings Call Transcript
Unknown8-5
The earnings call summary presents a mixed outlook: strong product innovation and market strategy are offset by uncertainties in tariffs and CMS proposals. The Q&A session reveals management's cautious optimism, but with some unclear responses. Financial performance and guidance remain stable, yet the lack of clear answers on certain risks tempers enthusiasm. Given these factors, a neutral rating is appropriate as the stock may not significantly change over the next two weeks.
Smith & Nephew plc (SNN) Q1 2025 Earnings Call Transcript
Unknown5-2
The earnings call presents a mixed picture: moderate revenue growth, strong performance in specific segments, and effective tariff mitigation strategies, but also challenges like headwinds in China and lack of share buybacks. The Q&A reveals optimism about future growth and margin improvements, but some concerns remain unaddressed. The absence of a share buyback program and the challenges in emerging markets balance the positives, leading to a neutral stock price prediction over the next two weeks.
Smith & Nephew plc (SNN) Q4 2024 Earnings Call Transcript
Unknown2-25
The earnings call presents a mixed picture. Financial performance shows growth in revenue and trading profit, but gross margins have declined slightly. The unchanged dividend and improved free cash flow are positive, while headcount reductions and cost savings indicate efficiency efforts. However, management's unclear responses in the Q&A, particularly regarding inventory reduction and competitive dynamics in China, suggest some uncertainty. The overall sentiment is neutral, with no strong catalysts for significant stock movement in the short term.
SNN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
